This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

U.S. National Institutes Of Health Recommend To Expand Its Scope Of Research In The Development Of Pluristem's PLX-RAD Cells For The Treatment Of Acute Radiation Syndrome

HAIFA, Israel, July 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, has recommended to Pluristem that NIAID expand the scope of its ongoing animal research using PLX-RAD cells for the treatment of acute radiation syndrome (ARS).

As previously announced on July 26, 2012, Pluristem accepted NIAID's invitation to submit PLX-RAD cells to the agency for this indication. Subsequently, NIAID's contract facilities have been studying the use of PLX-RAD cells on irradiated animals' hematological systems. NIAID has now recommended that the institute expand the focus of its work to better understand the mechanism of action for dose optimization. NIAID's initial work on the use of PLX-RAD cells included a screening assay examining the thirty-day survival of irradiated rodents given PLX-RAD or vehicle as a control. In this study mice were exposed to either 853, 872 or 904 cGy of total body gamma irradiation and injected intramusculary with two doses of two million PLX-RAD cells per dose or vehicle on days 1 and 5 following radiation (n=49-53 mice/group). Thirty-day survival was significantly increased in mice treated with PLX-RAD cells (p<0.0001) for all radiation doses. Overall survival time was also significantly increased in these mice (p=0.0004).  

"We are extremely pleased that the positive animal results obtained from NIAID have prompted them to recommend extending and expanding the scope of their investigation towards developing our PLX-RAD cells as a potential treatment for ARS," said Zami Aberman, Chairman and CEO of Pluristem. "Additionally, we believe the data generated from this collaboration will be very helpful in developing PLX-RAD for the indication of bone marrow failure following radio or chemotherapy."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,994.83 +282.17 1.59%
S&P 500 2,087.95 +26.93 1.31%
NASDAQ 4,945.8810 +54.6620 1.12%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs